ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock surged 7.34% in pre-market trading on Monday following the release of its third-quarter 2025 financial results, which showcased strong revenue growth and commercial progress for its flagship product, neffy® (epinephrine nasal spray).

The company reported total revenue of $32.5 million for Q3 2025, significantly beating analyst estimates of $28.7 million. This represents a remarkable 1,470% increase from the $2.1 million reported in the same period last year. The revenue growth was primarily driven by $31.3 million in neffy U.S. net product sales, demonstrating the successful commercial launch and growing adoption of the needle-free epinephrine treatment.

Despite the impressive top-line growth, ARS Pharmaceuticals posted a net loss of $51.2 million, or $0.52 per share, which was wider than the analyst consensus estimate of $0.47 per share. The increased loss reflects substantial investments in marketing and commercialization efforts, including a national direct-to-consumer campaign that has significantly boosted consumer awareness of neffy.

Investors appear to be focusing on the positive aspects of the report, including the strong sales momentum and the company's solid financial position. ARS Pharmaceuticals reported $288.2 million in cash, cash equivalents, and short-term investments as of September 30, 2025, which it believes will fund operations through expected cash-flow break-even. The company also highlighted progress in expanding neffy's global reach, with recent approvals in Japan and successful launches in European markets.